ThinkstockUnitedHealth Group Inc. (NYSE: UNH) released its third-quarter financial results before the markets opened on Thursday. The health insurance giant reported $1.65 in earnings per share (EPS) on $41.49 in revenue. That compared to…
Tetraphase Pharmaceuticals continues to reel from the spectacular and unexpected failure of its flagship candidate, eravacycline.
UnitedHealth Group is scheduled to report its third-quarter financial results Thursday before the markets open.
Axsome Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Can-Fite BioPharma announced that it has entered into definitive agreements with existing institutional investors in regard to a secondary offering.
Nabriva Therapeutics entered the market in mid-September, and now the quiet period has passed, allowing the underwriters can make calls.
Dimension Therapeutics expects to offer 5.5 million shares within the price range of $14 to $16 in an IPO valued up to $101.2 million.
Johnson & Johnson reported mixed third-quarter 2015 results before markets opened Tuesday morning.
ThinkstockAetna Inc. (NYSE: AET) may be worth quite a bit more than its current price, and that might be the case with or without its merger with Humana Inc. (NYSE: HUM). That is the…
Johnson & Johnson is scheduled to report its third-quarter financial results before the markets open on Tuesday.
Can-Fite Biopharma announced that its oncology drug candidate has been granted Orphan Drug Designation by the European Medicines Agency (EMA).
Theravance announced on Monday that Vibativ demonstrated positive clinical outcomes for patients with staphylococcus aureus (S. aureus) bacteremia and methicillin-resistant S. aureus (MRSA) osteomyelitis
Eli Lilly is suffering after bad news about its evacetrapib for high-risk atherosclerotic cardiovascular disease.
The September 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.